AZN

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 26.64% Potential Upside

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, has long garnered attention for its innovation and robust product pipeline. As a leading entity in the general drug manufacturing industry,..

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio...

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 28.83% Potential Upside in the Healthcare Sector

AstraZeneca PLC (AZN), a prominent player in the healthcare sector, is capturing investor attention with a tantalizing potential upside of 28.83%. With its robust market capitalization of $266.15 billion, AstraZeneca..

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 14.93% Potential Upside for Investors

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, continues to capture investor interest with its robust financial performance and strategic initiatives in the biopharmaceutical domain. As of the latest..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 19% Upside and Robust Revenue Growth

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to draw attention from investors with its impressive market cap of $292.2 billion and a promising potential upside of 19.15%...

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer...

AstraZeneca PLC (AZN) Stock Analysis: Robust Growth and Analyst Confidence Propel a 28% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a stalwart in the healthcare sector, is drawing significant investor interest with its impressive market cap of $271.29 billion and a promising potential upside of 28.33%...

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 25.59% Potential Upside with Strong Buy Ratings

AstraZeneca PLC (AZN), a titan in the healthcare sector, has garnered significant attention from investors, offering a potential upside of 25.59% as per recent analyst evaluations. With a market capitalization..

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer...

AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential

AstraZeneca PLC (AZN) presents a compelling case for investors seeking opportunities within the healthcare sector. With its headquarters in Cambridge, United Kingdom, this biopharmaceutical titan boasts a market capitalization of..

AstraZeneca PLC (AZN) Stock Analysis: Evaluating a Promising 20.91% Upside Potential

AstraZeneca PLC (AZN), a titan in the healthcare sector, holds a prominent position in the drug manufacturing industry. With a staggering market capitalization of $287.95 billion, this UK-based biopharmaceutical powerhouse..

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free..

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options...

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and a 20% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a prominent player in the healthcare sector, stands as a titan among global drug manufacturers. With a market capitalization of $290.06 billion, this UK-based biopharmaceutical company..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and 23.63% Potential Upside

AstraZeneca PLC (AZN), a leading biopharmaceutical company headquartered in Cambridge, UK, continues to captivate investor interest with its robust pipeline of prescription medicines and strategic collaborations. As a stalwart in..

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05..

AstraZeneca PLC (AZN): Investor Outlook Reveals 22.39% Upside Potential and Strong Buy Ratings

AstraZeneca PLC (AZN) continues to draw investors’ attention with its robust position in the healthcare sector, specifically within the drug manufacturing industry. Based in the United Kingdom, the company is..

AstraZeneca PLC (AZN) Stock Analysis: Unpacking a 21% Potential Upside Opportunity

AstraZeneca PLC (AZN), a leading player in the biopharmaceutical sector, continues to capture investor attention with its robust market presence and a significant potential upside. This UK-based healthcare giant, with..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and 11.51% Potential Upside

AstraZeneca PLC (AZN), a leading biopharmaceutical company based in the United Kingdom, remains a compelling choice for investors seeking exposure to the healthcare sector. With a market capitalization of $294.17..

Search

Funds

AZN

Astrazeneca secures global rights to Zegfrovy in EGFR-mutated lung cancer

Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio...

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer...

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer...

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival...

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options...

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials...
Search

Funds

AZN

FTSE 100

Funds